Treatment of chronic hepatitis B virus infection: An Asia-Pacific perspective

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 1, 1999, Pages 3-12

  Lau, George K K ^a   Carman, William F ^b   Locarnini, Stephen A ^c   Okuda, Kunio ^d   Lu, Zhi Meng ^e   Williams, Roger ^f   Lam, Shiu Kum ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d CHIBA UNIVERSITY   (Japan)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Asian; Consensus; Hepatitis B infection; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; DNA POLYMERASE; DNA VACCINE; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; THYMOSIN ALPHA1; VIRUS DNA;

ASIA; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; HEPATITIS B; HUMAN; IMMUNOMODULATION; PACIFIC ISLANDS; PRIORITY JOURNAL; REVIEW;

EID: 0033021170     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01812.x     Document Type: Review

References (95)

1. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of hepatitis B by immunization: Global perspective. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss Inc, 1988; 967-9.
2. Lau GKK, Wu PC, Lai CL. Natural history of chronic HBV infection. HK Med. J. 1997; 3: 283-8.
3. Lok ASF. Treatment of chronic hepatitis B. J. Viral Hepatitis 1994; 1: 105-24.
4. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
5. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B treated with interferon alpha. Gastroenterology 1993; 105: 1833-8.
6. Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hep. Rev. 1995; 2: 1-35.
7. Doong SL, Tsai DH, Schinazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′-3′-didieoxy-3′-thiacytidine and related analogues. Proc. Natl Acad. Sci. USA 1991; 88: 8495-9.
8. Shaw T, Amor P, Civitico G et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside against duck hepatitis B virus. Antimicrob. Agents Chemother. 1994; 38: 719-23.
9. Heijtink RA, De Wilde GA, Kruining J et al. Inhibitory effect of 9-(2-phosphomethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 1993; 21: 141-53.
10. Main J, Brown JL, Howells C et al. A double blind placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hep. 1996; 3: 211-15.
11. Trepo C, Jezed P, Atkinson GE et al. Efficacy of famciclovir in chronic hepatitis B. Results of a dose finding study. Hepatology 1996; 24: A188.
12. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
13. Lai CL, Ching CK, Tung AK et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 1997; 25: 241-4.
14. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B. Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl Acad. Sci. USA 1996; 93: 7213-18.
15. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 1997; 71: 169-78.
16. Pol S, Couillin I, Michel ML et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Acta Gastroen-terol. Belg. 1998; 61: 228-32.
17. Ilan Y, Nagler A, Shouval D et al. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipients following treatment with peripheral blood lymphocytes from immune donors. Clin. Exp. Immunol. 1994; 97: 299-302.
18. Lau GKK, Lok ASF, Liang R et al. Clearance of HBsAg after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 1997; 25: 1497-501.
19. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995; 95: 341-9.
20. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine Anti-HBs complex as an approach for vaccine therapy. Lancet 1995; 345: 1575-6.
21. Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig. Dis. 1992; 10: 46-52.
22. Nicoll A, Locarnini S. Review: Present and future directions in the treatment of chronic hepatitis B infection. J. Gastroenterol. Hepatol. 1997; 12: 843-54.
23. Carman WF, Jacyn MR, Hadziyannis SJ et al. Mutation preventing formation of HBe antigen in patients with chronic hepatitis B infection. Lancet 1989; ii: 588-90.
24. Hadziyannis SJ. Hepatitis Be antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hep. Rev. 1995; 1: 7-36.
25. Barnaba V, Balsano F. Immunological and molecular basis of viral persistence: The hepatitis B virus model. J. Hepatol. 1992; 14: 391-400.
26. Lau GKK, Carmen WF, Wang BE. Immunological approaches to the breakdown of hepatitis B viral persistence. Chin. Med. J. 1998; 111: 560-4.
27. Bertoletti A, Ferrari C, Fiaccadori F et al. HLA class-I restricted human cytotoxicT cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl Acad. Sci. USA 1991; 88: 10445-9.
28. Penna A, Fowler P, Bertoletti A et al. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: Characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J. Virol. 1992; 66: 1193-8.
29. Missale G, Redeker A, Person J et al. HLA-A31 and Aw68 restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J. Exp. Med. 1993; 177: 751-62.
30. Nayersina R, Fowler P, Guilhot S et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993; 150: 4659-71.
31. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 1995; 181: 1047-58.
32. Lok ASF, Liang RH, Chung H. Recovery from hepatitis B (letter). Ann. Intern. Med. 1992; 116: 957.
33. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by BMT from a hepatitis B immune donor. Gastroenterology 1993; 104: 1818-21.
34. Chen PM, Fan S, Liu CJ et al. Changing of hepatitis B virus markers in patients with bone marrow transplanta-tion. Transplantation 1990; 49: 708-13.
35. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77: 195-200.
36. Locasciulli A, Bacigalupo A, Van-Lint MT, Chemello L, Pontisso P, Occhini D et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: A report of 30 cases. Bone Marrow Transplant 1990; 6: 25-9.
37. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23.
38. Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon α-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J. Hepatol. 1990; 11: S113-17.
39. Perrillo RP, Schiff E, Davis GL et al. A randomised controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 1990; 323: 295-301.
40. Lau GKK, Lim WL, Lok ASF. Nine years follow-up after interferon (IFN) treatment for chronic hepatitis B (CHB) in Chinese patients. Hepatology 1997; 26: 259A.
41. Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J. Gastroenterol. Hepatol. 1997; 12: S346-53.
42. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomised controlled trial. J. Hepatol. 1994; 20: 175-80.
43. Fevery J, Elewant A, Michielsen P et al. Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic hepatitis B. A prospective double-blind Belgian-Dutch study. J. Hepatol. 1990; 11 (Suppl.): S108-12.
44. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl Acad. Sci. USA 1986; 83: 6107-11.
45. Serrate SA, Schulof RS, Leonidas L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production and interleukin 2 receptor expression by thymic hormones. J. Immunol. 1987; 139: 2338-43.
46. Mutchnick MG, Jaurequi JI, Shafritz DA. Sustained response to thymosin therapy in patients with chronic hepatitis. Hepatology 1992; 16: 66A.
47. 1 in patients with chronic hepatitis B: A randomised, controlled trial. Hepatology 1998; 27: 1383-7.
48. Lu ZM, Gao J, Yao GB et al. A comparative trial of thymosin alone and thymosin plus interferon in the treatment of Chinese patients with chronic hepatitis B (CHB). Hepatology 1997; 26: 426A.
49. Ferrari C, Bertoletti A, Penna A et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 1991; 88: 214-22.
50. Tsai SL, Chen DS, ChangTH. Peptide recognition and competition, T cell receptor usage, HLA restriction elements of T cell clones specific to a determinant of hepatitis B virus core, e antigen in chronic type B hepatitis. In: Nishinoka K, Susuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag, 1994; 162-7.
51. Guilhot S, Fowler P, Portillo G et al. Hepatitis B virus (HBV) specific cytolytic T cell response in humans: Production of target cells by stable expression of HBV-proteins in immortalized human B cell lines. J. Virol. 1992; 66: 2670-8.
52. Tsai SL, Chen MY, Lai MY et al. Acute exacerbations of chronic hepatitis B are accompanied by increased T cell responses to hepatitis B core and e antigens. J. Clin. Invest. 1992; 89: 87-96.
53. Heathcote J, McHutchison K, Benner T et al. CY-1899: A therapeutic vaccine for chronic hepatitis B. Hepatology 1996;24:283A.
54. Celis E, Ou D, Otvos L. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferation and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J. Immunol. 1988; 140: 1808-15.
55. Wen YM, Xiong SD, Zhang W. Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. J. Gen. Virol. 1994; 75: 335-9.
56. Wen YM, Zhang W, Xu YY, Luo YF, Li PY. Elimination of immune tolerance to hepatitis virus in an animal model. Chin. Med. J. 1992; 105: 199-203.
57. Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in non-responder mice. J. Virol. 1995; 69: 5929-34.
58. Davis HL, Schirmberk R, Reimann J et al. DNA-mediated immunization in mice induces a potent MHC classI restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene Ther. 1995; 6: 1447-56.
59. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
60. Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus 1. Proc. Natl Acad. Sci. USA 1993; 90: 4156-60.
61. Xiang ZQ, Spitalnick S, Tran M et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induce protective immunity against rabies virus. Virology 1994; 199: 132-40.
62. Hervas-Stubbs S, Lasarte JJ, Sarobe P et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J. Hepatol. 1997; 27: 726-37.
63. Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a non-cytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci USA 1994; 91: 3764-8.
64. Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol. 1997; 27: 572-7.
65. Summers J, Mason W. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-15.
66. Mason WS, Taylor J, Hull R. Retroid virus genome replication. Adv. Virus Res. 1987; 32: 35-96.
67. Shaw T, Locarnini S. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy in viral hepatitis. Liver 1995; 15: 169-84.
68. Vere Hodge RA. Review: Antiviral portraits series, number 3. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 1993; 4: 67-84.
69. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 996-1002.
70. Chang CN, Doong SL, Zhou JH et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxycytidme-3′-thiacytidine in the inhibition of hepatitis B virus agents. J. Biol. Chem. 1992; 267: 13 938-42.
71. Zoulim F, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washmgton DC: American Society for Microbiology, 1995; 182.
72. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 1996; 93: 4398-402.
73. Milich DR, Jones JE, Hughes JL et al. Is a function of the secreted hepatitis B e antigen to induce immunological tolerance in utero? Proc. Natl Acad. Sci. USA 1990; 87: 6599-603.
74. Jansen RN, Johnson LC, Averett DR. High capacity in vitro assessment of anti hepatitis B virus compound selectivity by a virion specific polymerase chain reaction assay. Antimicrob. Agents Chemother. 1993; 37: 441-7.
75. Benharnou Y, Dohin E, Lunel-Fabiani F et al. Effect of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396-7.
76. Lai CL, Liaw YF, Leung N et al. A 12 month course of lamivudine (100 mg qd) therapy improved liver histology: Results of a placebo controlled multicentre study in Asia. J. Hepatol. 1997; 26 (Suppl. 1): 79.
77. Lau GKK, Liang RHS, Chiu EKW, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case-controlled study. Bone Marrow Transplant. 1997; 19: 795-9.
78. Hoofnagle JH, Dusheiko GM, Schaefer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Int. Med. 1982; 96: 447-9.
79. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroemerology 1991; 100: 182-8.
80. Lau GKK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J. Hepatol 1998; 28: 359-68.
81. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 359: 20-2.
82. Aye TT, Bartholomeusz A, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 1997; 26: 1148-53.
83. De Alan RA, Bartholomeusz A, Locarnini S et al. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: Primary famciclovir resistance followed by lethal hepatitis during acquired lamivudine resistance. J. Hepatol. 1997; 26 (Suppl. 1): 77.
84. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
85. Tipples GA, Ma MM, Fischer KP et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
86. Honkoop P, Niesters HG, de Man Ram et al. Lamivudine resistance in immunocompetent chronic hepatitis B. J. Hepatol. 1997; 26: 1393-5.
87. Kruger T, Tillman HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation. Hepatology 1995; 22: 219A.
88. Naoumov NV, Chokshi S, Smith H et al. Emergence and characterisation of lamivudine resistant hepatitis B virus variant. Hepatology 1996; 24: 282A.
89. Tillman HL, Trautwein C, Kruger M et al. Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation. J. Hepatol. 1997; 26 (Suppl. 1): 153.
90. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
91. Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-1-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob. Agents Chemother. 1996; 40: 1957-60.
92. Schinazi RF, Lloyd Jr RM, Nguyen MH et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 1993; 37: 875-81.
93. De Jong MC, Boucher CAB, Galasso GJ et al. Consensus symposium on combined antiviral therapy. Antiviral Res. 1995; 29: 5-29.
94. College D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-25.
95. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234-7.